Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a single ketamine infusion quiet the obsessive mind?

NCT ID NCT02624596

Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study tests whether a single low dose of ketamine can quickly reduce obsessive-compulsive disorder (OCD) symptoms. Adults with OCD will receive either ketamine or a comparison drug, and researchers will measure symptom changes using a standard OCD scale. The trial also uses brain imaging to explore how ketamine affects brain chemistry, aiming to understand why it might work.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ketamine (a single intravenous infusion)
What this could lead to
If successful, this could point toward a fast-acting treatment for OCD and reveal brain mechanisms behind symptom relief.
What could go wrong
This is a phase 2 trial with a single dose, so effects may be short-lived or not work for everyone. Ketamine can cause temporary side effects like dissociation or nausea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2016

Finished

Jun 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for participants with OCD: * age 18-65 * Primary diagnosis of OCD * Sufficient severity of OCD symptoms * ability to tolerate a treatment-free period * capacity to provide informed consent Inclusion criteria for healthy controls: * ages 18-65 * capacity to provide informed consent Exclusion criteria for participants with OCD: * Psychiatric or medical conditions that make participation unsafe * pregnant or nursing females * concurrent use of any medications that might increase the risk of participation (e.g. drug interactions) * presence of metallic device or dental braces Exclusion criteria for healthy controls: * any current or lifetime psychiatric diagnosis * pregnant or nursing females * major medical or neurological problem * presence of metallic device or dental braces

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obsessive compulsive disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

obsessive-compulsive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obsessive compulsive disorder

Contacts and locations

Locations

  • Stanford University

    Stanford, California, 94305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.